Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Fang, Zhiqing ^a   Tang, Yueqing ^a   Fang, Juanjuan ^b   Zhou, Zunlin ^a   Xing, Zhaoquan ^a   Guo, Zhaoxin ^a   Guo, Xiaoyu ^c   Wang, Weichang ^a   Jiao, Wei ^a   Xu, Zhonghua ^a   Liu, Zhaoxu ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b Department of Anesthesiology   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SIMVASTATIN; STAT3 PROTEIN; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CANCER; METASTASIS; METASTASIS INHIBITION; MOLECULAR DYNAMICS; MORPHOLOGY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, RENAL CELL; CELL MOTION; DRUG EFFECTS; METABOLISM; NEOPLASM METASTASIS; NICK END LABELING; NUDE MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IN SITU NICK-END LABELING; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM METASTASIS; PHOSPHORYLATION; RNA INTERFERENCE; SIMVASTATIN; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84877857216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062823     Document Type: Article

References (57)

1. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, et al. (2010) Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 58: 819-828.
2. Basso M, Cassano A, Barone C, (2010) A survey of therapy for advanced renal cell carcinoma. Urol Oncol 28: 121-133.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA, (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23: 202-212.
4. Linehan WM, Zbar B, (2004) Focus on kidney cancer. Cancer Cell 6: 223-228.
5. Motzer RJ, Russo P, (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408-417.
6. Thillai K, Allan S, Powles T, Rudman S, Chowdhury S, (2012) Neoadjuvant and adjuvant treatment of renal cell carcinoma. Expert Rev Anticancer Ther 12: 765-776.
7. Herrmann E, Bierer S, Wulfing C, (2010) Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 28: 303-309.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
9. Miyake H, Harada KI, Kusuda Y, Fujisawa M, (2012) Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. Int J Clin Oncol doi:10.1007/s10147-012-0492-7.
10. Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, et al. (2010) Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 14: 1-184, iii-iv.
11. Thurnher M, Nussbaumer O, Gruenbacher G, (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18: 3524-3531.
12. Takahashi HK, Nishibori M, (2007) The antitumour activities of statins. Curr Oncol 14: 246.
13. Schonbeck U, Libby P, (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109: II18-26.
14. Blum A, Shamburek R, (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330.
15. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA, (2000) Statins and the risk of dementia. Lancet 356: 1627-1631.
16. Campese VM, Park J, (2007) HMG-CoA reductase inhibitors and the kidney. Kidney Int 71: 1215-1222.
17. Fried LF, (2008) Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74: 571-576.
18. Sassano A, Platanias LC, (2008) Statins in tumor suppression. Cancer Lett 260: 11-19.
19. Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, et al. (2012) Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 12: 409.
20. Hoque A, Chen H, Xu XC, (2008) Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17: 88-94.
21. Brown M, Hart C, Tawadros T, Ramani V, Sangar V, et al. (2012) The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 106: 1689-1696.
22. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, et al. (2008) Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 372: 356-361.
23. Sanchez CA, Rodriguez E, Varela E, Zapata E, Paez A, et al. (2008) Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 26: 698-707.
24. Gopalan A, Yu W, Sanders BG, Kline K, (2012) Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329 (1):: 9-16.
25. Kotamraju S, Williams CL, Kalyanaraman B, (2007) Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 67: 7386-7394.
26. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, et al. (2010) Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med 26: 735-741.
27. Jiang J, Nilsson-Ehle P, Xu N, (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5: 4.
28. Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, et al. (2011) NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One 6: e18306.
29. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, et al. (2008) Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 123: 951-957.
30. Khurana V, Caldito G, Ankem M, (2008) Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 71: 118-122.
31. Yan L, Xing Z, Guo Z, Fang Z, Jiao W, et al. (2013) Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy. PLoS One 8: e55790.
32. Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, et al. (2011) Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 6: e28813.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ, (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
34. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, et al. (1998) Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281: 2027-2031.
35. Bjornsti MA, Houghton PJ, (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
36. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
37. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
38. Zhou Q, Liao JK, (2010) Pleiotropic effects of statins.- Basic research and clinical perspectives. Circ J 74: 818-826.
39. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
40. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
41. Clendening JW, Penn LZ, (2012) Targeting tumor cell metabolism with statins. Oncogene 31: 4967-4978.
42. Osmak M, (2012) Statins and cancer: current and future prospects. Cancer Lett 324: 1-12.
43. Karp I, Behlouli H, Lelorier J, Pilote L, (2008) Statins and cancer risk. Am J Med 121: 302-309.
44. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, et al. (2005) Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62: 1363-1370.
45. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, et al. (2006) Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25: 877-887.
46. Roy M, Kung HJ, Ghosh PM, (2011) Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res 1: 542-561.
47. Zhang J, Yang Z, Xie L, Xu L, Xu D, et al. (2012) Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol 45 (3):: 745-752.
48. Pelaia G, Gallelli L, Renda T, Fratto D, Falcone D, et al. (2012) Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell Prolif 45: 557-565.
49. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, et al. (2005) Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93: 319-330.
50. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS, (2002) Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56: 133-142.
51. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222.
52. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR, (2011) Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 336: 496-505.
53. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
54. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
55. Bowman T, Garcia R, Turkson J, Jove R, (2000) STATs in oncogenesis. Oncogene 19: 2474-2488.
56. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, et al. (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322.
57. Guo Y, Xu F, Lu T, Duan Z, Zhang Z, (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904-910.